Sirolimus
Sirolimus
Definition
A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)
Also known as 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2, AY 22989, AY-22989, AY22989, RAPA, Rapamune, RAPAMYCIN, SILA 9268A, SILA-9268A, SILA9268A, SIROLIMUS, WY 090217, WY-090217, WY090217 — per NCIT
Also identified as
- ATC L01EG per NCIT
- ATC L04AH per NCIT
- ATC S01XA per NCIT
- NCIT NCIT:C1212 per NCIT
Indications
| Disease | Relation | Source |
|---|---|---|
| Graft versus host disease | may prevent | MEDRT · Public domain (U.S. Government work) |
| Lymphangioleiomyomatosis | may treat | MEDRT · Public domain (U.S. Government work) |
| Neoplasm with perivascular epithelioid cell differentiation | may treat | MEDRT · Public domain (U.S. Government work) |